Spyre Therapeutics, Inc. (SYRE) Down 4.9% — Is It Time to Peel Out?
Spyre Therapeutics, Inc. (SYRE) is losing ground in today's session. The stock is currently changing hands at $101.59 on the NASDAQ, a $5.23 decline from the prior close of $106.82. The pullback comes just three days after the stock set its 52-week high of $110.64 on November 9, 2026, and it leaves shares roughly 8.2% below that level. Today's move barely dents a large run. The stock still trades about 370% above the bottom of its 52-week range of $21.63, which shows how much optimism is already priced into the name.
Volume is light so far, with approximately 137,186 shares traded against a 90-day average of roughly 1.18 million. The decline is happening on a fraction of normal turnover with the session still open.
Why Spyre Therapeutics, Inc. Price is Moving Lower
The clearest driver is a broad Health Care selloff. The SPDR S&P Biotech ETF (XBI) was down 3.63% at 10:26 a.m. ET, and Spyre's losses have tracked that weakness through the morning. SYRE was down a more modest 2.78% at 9:38 a.m. ET before the decline widened as sector selling deepened. Other Health Care names are also lower. Moderna, Inc. (MRNA) is off 3.97%, and Revolution Medicines, Inc. (RVMD) has slipped 2.01%. Spyre has climbed sharply into its November 9 high, so it was exposed to a pullback once the group turned lower.
The company-specific backdrop adds to the caution. On November 3, Spyre reported a Q3 loss of $0.94 per share, compared with the consensus estimate of a $0.785 loss, a $0.155 miss. Net loss widened to $96.1 million from $11.2 million a year earlier. Research and development spending nearly doubled to $89.2 million from $45.2 million as the company pushed several programs through mid-stage trials. That spending pace is expected for a clinical-stage developer, but it raises the stakes on every data readout ahead.
The same update brought a clinical setback. SPY072 missed its main endpoints in Phase 2 studies for psoriatic arthritis and axial spondyloarthritis, and Spyre said it will stop developing the drug for rheumatic diseases. That removes one leg of the pipeline, although the company reported positive ulcerative colitis results for its three other candidates. Management pointed to $1.47 billion in pro-forma cash and a runway into the second half of 2029. The next major catalyst is combination-trial data expected in Q3 of 2027, which is a long wait for a stock trading near its highs during sector weakness.
What is the Spyre Therapeutics, Inc. Rating - Should I Sell?
Weiss Ratings assigns SYRE a D- rating. The rating was upgraded on 3/9/2026. Current recommendation is Sell. The upgrade earlier this year did not lift the stock out of Sell territory. The D- reflects a company whose share price and balance sheet have outrun its operating fundamentals, which remain those of a pre-revenue drug developer.
The Excellent ratings on the Solvency Index and the Total Return Index reflect real strengths. The Solvency Index rating is supported by $1.47 billion in pro-forma cash and a stated runway into the second half of 2029. That cushion should carry Spyre past its 2027 combination readout without forcing a near-term capital raise.
The Total Return Index rating needs little explanation for a stock that has climbed from $21.63 to above $100 within a year. Shareholders who held through that stretch have been well rewarded.
Where the picture turns is everything tied to the underlying business. The Very Weak rating on the Growth Index reflects a company with no commercial revenue and a quarterly net loss that widened to $96.1 million from $11.2 million a year ago. The pipeline also lost a rheumatology indication this quarter.
The Efficiency Index carries the same Very Weak rating. Trailing EPS of -$2.74 and a forward P/E of -39.03 show that a $10.14 billion valuation rests on future clinical success rather than current earnings.
The Weak Volatility Index reflects a stock that has swung across a nearly fivefold 52-week range. Today's sector-driven drop of almost 5% shows how quickly momentum can reverse when biotech sentiment sours.
Within the Health Care sector, Spyre sits alongside Moderna, Inc. (MRNA, D-), Revolution Medicines, Inc. (RVMD, D-), and Natera, Inc. (NTRA, D-). It trails IQVIA Holdings Inc. (IQV, D+) and Zoetis Inc. (ZTS, D+), both of which carry somewhat better risk/reward profiles in Weiss's framework. That peer group suggests the Sell signal reflects broad caution across much of the sector rather than an outlier judgment on Spyre alone.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) is a clinical-stage Health Care company. Based in Waltham, Massachusetts, the company develops antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and it has also pursued rheumatic disease indications. Spyre was incorporated in 2013 and operated as Aeglea BioTherapeutics, Inc. until it adopted its current name in November 2023, a rebrand that came with a strategic pivot toward immunology.
The pipeline targets three of the most validated pathways in inflammatory disease. SPY001 is a humanized monoclonal IgG1 antibody in Phase 2 development. It is designed to bind selectively to the α4β7 integrin, the same target behind established gut-selective IBD therapy. SPY002 and SPY072 are anti-TL1A antibodies aimed at a pathway that has drawn heavy industry interest. Following the recent Phase 2 results, SPY072 is no longer being developed for rheumatic diseases. SPY003 is a Phase 2 program designed to bind interleukin-23 (IL-23).
Spyre's central strategic idea is combination therapy. The company is building pairings of its own antibodies: SPY120 combines anti-α4β7 and anti-TL1A, SPY130 combines anti-α4β7 and anti-IL-23, and SPY230 combines anti-TL1A and anti-IL-23. If combining mechanisms can push efficacy beyond what single agents achieve in IBD, Spyre would hold a distinctive position in a market crowded with large-cap competitors. Owning every component of each combination in-house gives the company flexibility in trial design and development, but the approach must still be proven in the clinic, where the 2027 combination data will be the defining test.
Investor Outlook
Spyre Therapeutics, Inc. (SYRE) carries a Weiss Rating of D- (Sell). A strong cash position and a remarkable one-year run sit against widening losses, a discontinued rheumatology program, and a key readout that is still well over a year away. Investors should watch broader biotech sentiment, quarterly cash burn relative to the 2029 runway, and any updates ahead of the combination-trial data expected in Q3 of 2027. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--